Abstract:BACKGROUND: The surgical burden of disease is substantial, but little is known about the associated economic consequences. We estimate the global macroeconomic impact of the surgical burden of disease due to injury, neoplasm, digestive diseases, and maternal and neonatal disorders from two distinct economic perspectives.METHODS: We obtained mortality rate estimates for each disease for the years 2000 and 2010 from the Institute of Health Metrics and Evaluation Global Burden of Disease 2010 study, and estimates of the proportion of the burden of the selected diseases that is surgical from a paper by Shrime and colleagues. We first used the value of lost output (VLO) approach, based on the WHO's Projecting the Economic Cost of Ill-Health (EPIC) model, to project annual market economy losses due to these surgical diseases during 2015-30. EPIC attempts to model how disease affects a country's projected labour force and capital stock, which in turn are related to losses in economic output, or gross domestic product (GDP). We then used the value of lost welfare (VLW) approach, which is conceptually based on the value of a statistical life and is inclusive of non-market losses, to estimate the present value of long-run welfare losses resulting from mortality and short-run welfare losses resulting from morbidity incurred during 2010. Sensitivity analyses were performed for both approaches.FINDINGS: During 2015-30, the VLO approach projected that surgical conditions would result in losses of 1·25% of potential GDP, or $20·7 trillion (2010 US$, purchasing power parity) in the 128 countries with data available. When expressed as a proportion of potential GDP, annual GDP losses were greatest in low-income and middle-income countries, with up to a 2·5% loss in output by 2030. When total welfare losses are assessed (VLW), the present value of economic losses is estimated to be equivalent to 17% of 2010 GDP, or $14·5 trillion in the 175 countries assessed with this approach. Neoplasm and injury account for greater than 95% of total economic losses with each approach, but maternal, digestive, and neonatal disorders, which represent only 4% of losses in high-income countries with the VLW approach, contribute to 26% of losses in low-income countries.INTERPRETATION: The macroeconomic impact of surgical disease is substantial and inequitably distributed. When paired with the growing number of favourable cost-effectiveness analyses of surgical interventions in low-income and middle-income countries, our results suggest that building surgical capacity should be a global health priority.FUNDING: US National Institutes of Health/National Cancer Institute.

Estimating the indirect economic burden of cancer in Jordan: a retrospective observational study

The Economic Burden of Cancer in Canada from a Societal Perspective

The indirect costs of vaccine-preventable cancer mortality in the Middle East and North Africa (MENA)

Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007-2017

A systematic review of the economic burden of colorectal cancer

The burden of Cardiovascular diseases in Jordan: a longitudinal analysis from the global burden of disease study, 1990–2019

Estimates and Projections of the Global Economic Cost of 29 Cancers From 2020 to 2050

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review

Article The Burden of Esophageal Cancer in China From 2013 to 2030 A Dynamic Cohort Modeling Study

Burden and indirect cost of vaccine-preventable cancer mortality in Europe

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions

The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study

Cancer Care in Resource-Limited Countries: Jordan as an Example

The cost-of-illness of multiple sclerosis in Jordan

Toward a Framework to Assess the Financial and Economic Burden of Cervical Cancer in Low- and Middle-Income Countries: A Systematic Review

Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018

Measuring the Indirect Cost Associated with Advanced Non-Small Cell Lung Cancer: a Nationwide Cross-Sectional Study in China

A Prevalence-Based Cost-of-Illness Analysis from the Healthcare Provider Perspective

Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study

Global economic consequences of selected surgical diseases: a modelling study